MAP2K7 and cancer: Nevertheless, prior studies, our current in vitro data, and our GEMM in vivo results present a strong rationale for dual PI3K and MEK inhibitor therapy for cancer treatment and is thus being exploited in the clinic at the early-phase clinical trial level in other malignancies.44